Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 24, Issue 1, Pages e7-e10
http://dx.doi.org/10.1155/2013/256756
Original Article

Low Seroconversion after One Dose of AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine in Solid-Organ Transplant Recipients

Mariangela R Resende,1,2 Shahid Husain,1 Jonathan Gubbay,3 Lianne Singer,4 Edward Cole,4 Eberhard L Renner,4 and Coleman Rotstein1

1Division of Infectious Diseases, University of Toronto, University Health Network, Toronto, Ontario, Canada
2Postdoctoral Scholarship National Council for Scientific and Technological Development (CNPq), University of Campinas, Sao Paulo, Brazil
3Public Health Laboratory – Toronto, Ontario Agency for Health Protection and Promotion, Canada
4Multi-Organ Transplant Program, University of Toronto, University Health Network, Toronto, Ontario, Canada

Copyright © 2013 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

BACKGROUND: Immunocompromised individuals are more susceptible to complications produced by influenza infection. As a result, solid-organ transplant (SOT) recipients were targeted as a priority group to receive AS03-adjuvanted H1N1 influenza vaccine during 2009.

OBJECTIVE: To evaluate seroconversion after one dose of adjuvanted pandemic influenza H1N1 (pH1N1) vaccine in SOT recipients.

METHODS: Adult SOT recipients were enrolled to receive one 3.75 μg dose of adjuvanted pH1N1 vaccine. Serological status was tested using a hemagglutination inhibition assay before and two and four weeks postvaccination.

RESULTS: The five SOT recipients (one liver, two kidney and two lung transplants) had a median age of 50 years (range 36 to 53 years), and three were male, who were a median time of three years (range two months to 15 years) post-transplant. All patients were on a double or triple immunosuppressive regimen. The prevaccination pH1N1 titre was 1:10 in four patients and 1:40 in one patient. Seroprotection was observed only in one patient, with a rise in titre from 1:40 at baseline to 1:320 at both two and four weeks after vaccination. This lung transplant recipient had documented previous infection with pH1N1.

CONCLUSION: Results of the present small study call into question whether one dose of adjuvanted pH1N1 vaccine can provide seroprotection in SOT recipients.